Proprietary Programs: Spin Out

Proprietary Programs: Spin Out 2018-11-17T23:06:33+00:00

Aurigene: Spin out of Oncology Pipeline

Aurigene is in the process of spinning out it pipeline of oncology programs into a US based New Company. More details of the same will be shared in the near future.

The pipeline comprises programs in small molecule I/O, Transcription Inhibitors and Protein degraders.

  • I/O pipeline includes first-in-class small molecule, inhibitors of CD47, TIGIT/PD-L1 and TIM3.
  • Molecularly targeted Transcription Inhibitors: Highly selective, orally available, covalent inhibitors of CDK7 and CDK12
  • Protein degraders for SMARCA2/4 and other targets